Translational and clinical implications of the genetic landscape of prostate cancer

Nature Reviews Clinical Oncology

Volumn 13, Issue 10, 2016, Pages 597-610

  Spratt, Daniel E ^a   Zumsteg, Zachary S ^b   Feng, Felix Y ^a   Tomlins, Scott A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALISERTIB; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; APALUTAMIDE; AZD 6738; AZD 8186; BIOLOGICAL MARKER; DACTOLISIB; DOCETAXEL; ENZALUTAMIDE; EPI 001; GALETERONE; GSK 2636771; IPATASERTIB; ISOCITRATE DEHYDROGENASE 1; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; ODM 201; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; RIBOCICLIB; SEVITERONEL; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VORINOSTAT; WNT PROTEIN; ANDROGEN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; TRANSCRIPTION FACTOR;

ANDROGEN SIGNALING; ATM GENE; AURKA GENE; BRACHYTHERAPY; BRCA2 GENE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE; CELL PROLIFERATION; CHD1 GENE; CHEK2 GENE; CIRCULATING TUMOR CELL; CRYOTHERAPY; DNA DAMAGE; DNA DAMAGE REPAIR; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ERG GENE; ETS GENE; ETV1 GENE; ETV4 GENE; ETV5 GENE; EXOME; FANCA GENE; FLI1 GENE; GENE EXPRESSION PROFILING; GENE FUSION; GENE TARGETING; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENOMIC LANDSCAPE; GENOMICS; HEREDITY; HIGH THROUGHPUT SCREENING; HOMOZYGOSITY; HUMAN; IDH1 GENE; MALE; MSH2 GENE; MYCN GENE; NEUROENDOCRINE PROSTATE CANCER; PALB2 GENE; PEG10 GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN PROTEIN INTERACTION; PTEN GENE; RAD51B GENE; RAD51C GENE; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SPINK1 GENE; SPOP GENE; STEREOTACTIC BODY RADIATION THERAPY; TMPRSS2 GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UPREGULATION; DISEASE COURSE; DRUG RESISTANCE; GENETICS; METABOLISM; NEUROENDOCRINE TUMOR; PROCEDURES; PROSTATIC NEOPLASMS; WNT SIGNALING PATHWAY;

ANDROGENS; CELL CYCLE; CELL PROLIFERATION; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MAP KINASE SIGNALING SYSTEM; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84973100750     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.76     Document Type: Review

References (214)

1. Mohler, J., Armstrong, A., & Bahnson, R. NCCN guidelines for patients®. Prostate cancer. National Comprehensive Cancer Network https://www.nccn.org/patients/guidelines/prostate/files/assets/common/downloads/files/prostate.pdf (2015
2. Spratt, D. E., et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 85, 686-692 (2013
3. Robinson, D., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015
4. Baca, S. C., et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666-677 (2013
5. Grasso, C. S., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012
6. Gundem, G., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015
7. Cooper, C. S., et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 47, 367-372 (2015
8. Boutros, P. C., et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736-745 (2015
9. Berger, M. F., et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011
10. Taylor, B. S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010
11. Barbieri, C. E., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012
12. Lalonde, E., et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5 year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 15, 1521-1532 (2014
13. Barbieri, C. E., & Tomlins, S. A. The prostate cancer genome: perspectives and potential. Paper presented at: Urologic Oncology: Seminars and Original Investigations. 33, 95-102 (2014
14. Demichelis, F., et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596-4599 (2007
15. Tomlins, S. A., et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur. Urol. 68, 568-569 (2015
16. Tomlins, S. A., et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007
17. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015
18. Huggins, C., & Hodges, C. V. Studies on prostatic cancer. Cancer Res. 1, 297 (1941
19. Wolf, D. A., Herzinger, T., Hermeking, H., Blaschke, D., & Hörz, W. Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol. Endocrinol. 7, 924-936 (1993
20. Knuuttila, M., et al. Castration induces up regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am. J. Pathol. 184, 2163-2173 (2014
21. Lin, C., et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139, 1069-1083 (2009
22. Heinlein, C. A., & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308 (2004
23. Bubendorf, L., et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59, 803-806 (1999
24. Miyoshi, Y., et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43, 225-232 (2000
25. Visakorpi, T., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406 (1995
26. Linja, M. J., et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550-3555 (2001
27. Chen, C. D., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004
28. Beer, T. M., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424-433 (2014
29. Cabot, R. C., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012
30. De Bono, J. S., et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011
31. Rathkopf, D. E., et al. ARN 509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA) [abstract]. Cancer Res. 74, CT239 (2014
32. Ryan, C. J., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013
33. Tran, C., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009
34. Clegg, N. J., et al. ARN 509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72, 1494-1503 (2012
35. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01946204 (2016
36. Fizazi, K., et al. Activity and safety of ODM 201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 15, 975-985 (2014
37. Fizazi, K., et al. ODM 201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: preclinical and phase I data [abstract]. J. Clin. Oncol. 31 (Suppl. 6), 65 (2013
38. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02200614 (2016
39. Azad, A. A., et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 21, 2315-2324 (2015
40. Arora, V. K., et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309-1322 (2013
41. Watson, P. A., Arora, V. K., & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701-711 (2015
42. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02012296 (2016
43. Dehm, S. M., & Tindall, D. J. Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer 18, R183-R196 (2011
44. Hu, R., et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72, 3457-3462 (2012
45. Hu, R., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22 (2009
46. Sun, S., et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715 (2010
47. Antonarakis, E. S., et al. AR V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038 (2014
48. Hornberg, E., et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6, e19059 (2011
49. Yamamoto, Y., et al. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Clin. Cancer Res. 21, 1675-1687 (2015
50. Amin, K. S., et al. A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells. Mol. Cancer Ther. 13, 341-352 (2014
51. Dalal, K., et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J. Biol. Chem. 289, 26417-26429 (2014
52. Bianchini, D., et al. First in human Phase I study of EZN 4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br. J. Cancer 109, 2579-2586 (2013
53. Myung, J. K., et al. An androgen receptor N terminal domain antagonist for treating prostate cancer. J. Clin. Invest. 123, 2948-2960 (2013
54. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02438007 (2016
55. Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer 120, 719-733 (2007
56. Heemers, H. V., et al. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol. 23, 572-583 (2009
57. Jozwik, K. M., & Carroll, J. S. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 12, 381-385 (2012
58. Sahu, B., et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 73, 1570-1580 (2013
59. Gormally, M. V., et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat. Commun. 5, 5165 (2014
60. He, B., et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc. Natl Acad. Sci. USA 111, 18261-18266 (2014
61. Asangani, I. A., et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 (2014
62. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02259114 (2016
63. Gregory, C. W., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315-4319 (2001
64. Agoulnik, I. U., et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 66, 10594-10602 (2006
65. Zhou, H. J., et al. SRC 3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65, 7976-7983 (2005
66. Tomlins, S. A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005
67. Yu, J., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010
68. Tu, J. J., et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT PCR and FISH on paraffin-embedded tissues. Mod. Pathol. 20, 921-928 (2007
69. Weischenfeldt, J., et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159-170 (2013
70. Tomlins, S. A., et al. Urine TMPRSS2: ERG plus PCA3 for individualized prostate cancer risk assessment. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2015.04.039 (2015
71. Tomlins, S. A., Palanisamy, N., Siddiqui, J., Chinnaiyan, A. M., & Kunju, L. P. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch. Pathol. Lab. Med. 136, 935-946 (2012
72. Park, K., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590-598 (2010
73. Furusato, B., et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 13, 228-237 (2010
74. Feng, F. Y., Brenner, J. C., Hussain, M., & Chinnaiyan, A. M. Molecular pathways: targeting ETS gene fusions in cancer. Clin. Cancer Res. 20, 4442-4448 (2014
75. Pettersson, A., et al. The TMPRSS2: ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 21, 1497-1509 (2012
76. Mounir, Z., et al. TMPRSS2: ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene 34, 3815-3825 (2015
77. Lucas, J. M., et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310-1325 (2014
78. Brenner, J. C., et al. Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011
79. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01576172 (2015
80. Bradley, D., et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862). Cancer 115, 5541-5549 (2009
81. Molife, L., et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 21, 109-113 (2010
82. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01075308 (2015
83. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00878436 (2015
84. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01174199 (2015
85. Saal, L. H., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA 104, 7564-7569 (2007
86. Ferraldeschi, R., et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur. Urol. 67, 795-802 (2015
87. Krohn, A., et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 181, 401-412 (2012
88. Yoshimoto, M., et al. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 21, 1451-1460 (2008
89. Reid, A., et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 102, 678-684 (2010
90. Carver, B. S., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011
91. Schwartz, S., et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell 27, 109-122 (2015
92. Klempner, S. J., Myers, A. P., & Cantley, L. C. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3 kinase pathway. Cancer Discov. 3, 1345-1354 (2013
93. Vincan, E., & Barker, N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin. Exp. Metastasis 25, 657-663 (2008
94. Hovelson, D. H., et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia 17, 385-399 (2015
95. Miyamoto, D. T., et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349, 1351-1356 (2015
96. Takebe, N., et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445-464 (2015
97. El Khoueiry, A. B., et al. A phase I first in human study of PRI 724 in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), 2501 (2013
98. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01302405 (2015
99. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01764477 (2015
100. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01606579 (2016
101. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01351103 (2016
102. Liu, J., et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224-20229 (2013
103. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01973309 (2015
104. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01957007 (2015
105. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02005315 (2015
106. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02069145 (2015
107. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02092363 (2015
108. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02050178 (2015
109. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01469975 (2015
110. Burotto, M., Chiou, V. L., Lee, J. M., & Kohn, E. C. The MAPK pathway across different malignancies: a new perspective. Cancer 120, 3446-3456 (2014
111. Mulholland, D. J., et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72, 1878-1889 (2012
112. Palanisamy, N., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793-798 (2010
113. Ghiam, A., et al. IDH mutation status in prostate cancer. Oncogene 31, 3826-3826 (2012
114. Kang, M. R., et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 125, 353-355 (2009
115. Mauzo, S. H., et al. Immunohistochemical demonstration of isocitrate dehydrogenase 1 (IDH1) mutation in a small subset of prostatic carcinomas. Appl. Immunohistochem. Mol. Morphol. 22, 284-287 (2014
116. Dang, L., et al. Cancer-associated IDH1 mutations produce 2 hydroxyglutarate. Nature 462, 739-744 (2009
117. Turcan, S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012
118. Figueroa, M. E., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010
119. Mardis, E. R., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009
120. Rohle, D., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626-630 (2013
121. Schumacher, T., et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324-327 (2014
122. Vousden, K. H., & Lane, D. P. p53 in health and disease. Nat. Rev. Molec. Cell Biol. 8, 275-283 (2007
123. Knudsen, E. S., & Knudsen, K. E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 8, 714-724 (2008
124. Turner, N. C., et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209-219 (2015
125. Finn, R. S., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2 negative, advanced breast cancer (PALOMA 1/TRIO 18): a randomised phase 2 study. Lancet Oncol. 16, 25-35 (2015
126. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02494921 (2016
127. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02555189 (2015
128. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02059213 (2015
129. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862-873 (2009
130. Toledo, L. I., et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721-727 (2011
131. Reaper, P. M., et al. Selective killing of ATM or p53 deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428-430 (2011
132. Bridges, K. A., et al. MK 1775, a novel Wee1 kinase inhibitor, radiosensitizes p53 defective human tumor cells. Clin. Cancer Res. 17, 5638-5648 (2011
133. Aarts, M., et al. Forced mitotic entry of S phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2, 524-539 (2012
134. Origanti, S., Cai, S., Munir, A. Z., White, L. S., & Piwnica-Worms, H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32, 577-588 (2013
135. Ma, C. X., et al. Targeting Chk1 in p53 deficient triple-negative breast cancer is therapeutically beneficial in human in mouse tumor models. J. Clin. Invest.122, 1541-1552 (2012
136. Do, K., et al. Phase I study of single-agent AZD1775 (MK 1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J. Clin. Oncol. 33, 3409-3415 (2015
137. Daud, A. I., et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK 8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J. Clin. Oncol. 33, 1060-1066 (2015
138. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02223923 (2016
139. Meyer, N., & Penn, L. Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990 (2008
140. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02110563 (2016
141. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02314052 (2015
142. Tolcher, A. W., et al. Safety and activity of DCR-MYC, a first in class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 33 (Suppl.), 11006 (2015
143. Kirschner, A. N., et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J. Natl Cancer Inst. 107, dju407 (2015
144. Delmore, J. E., et al. BET bromodomain inhibition as a therapeutic strategy to target c Myc. Cell 146, 904-917 (2011
145. Murga, M., et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 18, 1331-1335 (2011
146. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01563302 (2015
147. Page, B. D., et al. Small molecule STAT5 SH2 domain inhibitors exhibit potent antileukemia activity. J. Med. Chem. 55, 1047-1055 (2012
148. Karanika, S., Karantanos, T., Li, L., Corn, P., & Thompson, T. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 34, 2815-2822 (2014
149. Beltran, H., et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920-926 (2013
150. Alexandrov, L. B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
151. Pritchard, C. C., et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 5, 498 (2014
152. Grasso, C., et al. Integrative molecular profiling of routine clinical prostate cancer specimens. Ann. Oncol. 26, 1110-1118 (2015
153. Kumar, A., et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl Acad. Sci. USA 108, 17087-17092 (2011
154. Rizvi, N. A., et al. Mutational landscape determines sensitivity to PD 1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015
155. Snyder, A., et al. Genetic basis for clinical response to CTLA 4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014
156. Lord, C. J., Tutt, A. N., & Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 66, 455-470 (2015
157. Fong, P. C., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009
158. Audeh, M. W., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof of concept trial. Lancet 376, 245-251 (2010
159. Ledermann, J., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852-861 (2014
160. Kaufman, B., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244-250 (2015
161. Mateo, J., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697-1708 (2015
162. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01085422 (2013
163. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01972217 (2016
164. VanderWeele, D. J., Paner, G. P., Fleming, G. F., & Szmulewitz, R. Z. Sustained complete response to cytotoxic therapy and the PARP inhibitor veliparib in metastatic castration-resistant prostate cancer - a case report. Front. Oncol. 5, 169 (2015
165. Fong, P. C., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519 (2010
166. Ceccaldi, R., et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 75, 628-634 (2015
167. Polkinghorn, W. R., et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 3, 1245-1253 (2013
168. Goodwin, J. F., et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 3, 1254-1271 (2013
169. Spratt, D. E., et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res. 75, 4688-4696 (2015
170. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02297386 (2016
171. Eeles, R., et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol. 11, 18-31 (2014
172. Ostrander, E. A., & Udler, M. S. The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol. Biomarkers Prev. 17, 1843-1848 (2008
173. Tischkowitz, M., & Eeles, R. Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer. Lancet 362, 80; author reply 80 (2003
174. Liede, A., Karlan, B. Y., & Narod, S. A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol. 22, 735-742 (2004
175. Thompson, D., Easton, D. F., & Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94, 1358-1365 (2002
176. Raymond, V. M., et al. Elevated risk of prostate cancer among men with Lynch syndrome. J. Clin. Oncol. 31, 1713-1718 (2013
177. Ewing, C. M., et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 366, 141-149 (2012
178. Thompson Jr, I. M., et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl. J. Med. 369, 603-610 (2013
179. Klein, E. A., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306, 1549-1556 (2011
180. Djavan, B., et al. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech. Urol. 5, 139-142 (1999
181. Wise, A. M., Stamey, T. A., McNeal, J. E., & Clayton, J. L. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60, 264-269 (2002
182. Lindberg, J., et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur. Urol. 63, 347-353 (2013
183. Haffner, M. C., et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918-4922 (2013
184. Carreira, S., et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014
185. Bozic, I., et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013
186. Liu, W., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559-565 (2009
187. Hong, M. K., et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015
188. Comen, E., Norton, L., & Massague, J. Clinical implications of cancer self-seeding. Nat. Rev. Clin. Oncol. 8, 369-377 (2011
189. Taplin, M. E., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398 (1995
190. Holcomb, I. N., et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 69, 7793-7802 (2009
191. Beltran, H., Mosquera, J. M., & Rubin, M. A. in Prostate Cancer: A Comprehensive Perspective (ed. Tewari, A. K.) 277-282 (2013
192. Beltran, H., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487-495 (2011
193. Beltran, H., et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J. Clin. Oncol. 30, e386-e389 (2012
194. Pezaro, C. J., et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65, 270-273 (2014
195. Epstein, J. I., et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756-767 (2014
196. Small, E., et al. 760PD. Neuroendocrine prostate cancer (NEPC) in patients (PTS) with metastatic castration resistant prostate cancer (MCRPC) resistant to abiraterone (ABI) or enzalutamide (ENZ): preliminary results from the su2c/pcf/aacr west coast prostate cancer dream team (WCDT). Ann. Oncol. 25 (Suppl. 4), iv258-iv258 (2014
197. Tan, H. L., et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890-903 (2014
198. Chen, H., et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr. Relat. Cancer 19, 321-331 (2012
199. Akamatsu, S., et al. MP31 09 identification of a retro-transposon derived gene associated with progression to neuroendocrine prostate cancer. J. Urol. 191, e325 (2014
200. Kadakia, K. C., et al. Comprehensive serial molecular profiling of an 'N of 1' exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. J. Hematol. Oncol. 8, 1-7 (2015
201. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01792687 (2016
202. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01650194 (2016
203. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01949337 (2016
204. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01709734 (2016
205. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02012920 (2015
206. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02606123 (2015
207. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02144051 (2016
208. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01337518 (2012
209. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01485861 (2015
210. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01634061 (2015
211. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01884285 (2016
212. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01458067 (2016
213. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01682772 (2014
214. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01848067 (2015